Efficacy and safety of a Unani compound drug– Habb-e-Asgand in Waja‘al-Mafāsil (Rheumatoid Arthritis) cases- A preliminary study
Rheumatoid arthritis affects about 24.5 million people worldwide as of 2015. Modern medicine still eludes satisfactory cure for this problem. Therefore, world is looking forward for some traditional medicines in this direction. In the present work, therapeutic efficacy of a Unani compound drug Habb-e-Asgand has been evaluated at Regional Research Institute of Unani Medicine (RRIUM), Aligarh, during 2016-2018. A total of 68 patients were selected from the lot of patients attending outpatient department (OPD). The drug Habb-e-Asgand was given 2 tablets for 84 days and results evaluated statistically by one-way analysis of variance (ANOVA) followed by Dennett’s’ test. The results of the present study were evaluated on clinical, biochemical, and haematological parameters have amply demonstrated that the drug Habb-e-Asgand is therapeutically effective in the treatment of Waja ‘al-mafasil (rheumatoid arthritis). The study has also shown the drug non-toxic and safe. Further studies are suggested in large population.
Balghami (Phlegmatic), Damwi (Sanguine), Safrawi (Bilious) and Visual analogue score (VAS), Waja-al-Mafasil
Full Text: PDF (downloaded 404 times) PDF (downloaded 404 times)
- There are currently no refbacks.